<DOC>
	<DOCNO>NCT01216280</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability multiple oral dos Natura-alpha capsule administer patient active ulcerative colitis . This randomized , double-blind , placebo-controlled , parallel-design study . Up 75 patient complete study ( 20 25 patient per treatment group ) approximately 10-12 clinical site Unites States . Patients assign 1:1:1 ratio receive placebo , Natura-alpha 10 mg Natura-alpha 20 mg , b.i.d . Replacement patient may add , pending Sponsor approval , appear less 60 patient complete study .</brief_summary>
	<brief_title>Efficacy Tolerability Study Natura-Alpha Treatment Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-design study . Eligible patient moderate severe ulcerative colitis , define : - A Disease Activity Index ( DAI ) score 6 10 ( inclusive ) ; - Endoscopic evidence active ulcerative colitis ( DAI mucosal appearance sub score ≥2 ) assess flexible sigmoidoscopy unless colonoscopy clinically indicate ; - Rectal bleeding ( DAI sub score ≥1 ) ; - Physician 's Global Assessment ( PGA ) moderate disease ( DAI sub score ≥2 ) . Patients randomize receive placebo , 10 mg Natura-alpha 20 mg Natura-alpha . Patients self-administer assign dose orally 28 consecutive day , twice per day ( b.i.d ) approximately 8:00 8:00 pm . The effectiveness safety Natura-alpha evaluate baseline , 7 , 14 28 day treatment . Additional follow-up measurement take place 7 28 day post cessation treatment ( Day 35 Day 56 , respectively ) . Stool sample fecal calprotectin ( FC ) test optional blood sample ( 15 ml ) cytokine test collect analyzed sponsor-selected site lab exploratory analysis perform later date . Clinical response assess Physician 's Global Assessment ( PGA ) basis sigmoidoscopy ( Walkiewicz , Werlin et al . 2008 ) mucosal appearance ( DAI category ) . Sigmoidoscopy include histopathological examination ass disease severity change tissue inflammation conduct treatment ( Day 1 , Day 28 ) endoscopist site read one sponsor select central pathologist . Truelove-Richards histological grading system apply disease histological scoring ( Pullan , Rhodes et al . 1994 ; Zhong , Huang et al . 2005 ; Liang Ouyang 2008 ) . Safety labs adverse event ( AEs ) monitor duration study ( include 7 day follow visit ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Females must nonchildbearing potential evidence surgically sterile , postmenopausal least 12 month use acceptable contraception method . Subject require meet one follow criterion : 1 . Newly diagnose patient moderate severe ulcerative colitis evidence endoscopy histopathology , never medically treated ulcerative colitis , 2 . Patients moderate severe disease , define Disease Activity Index ( DAI ) score 610 ( inclusive ) Baseline Visit ( assess screen verified Day 1 ) , negative evaluation terminal ileum within 3 year screen visit , 3 . Patients active ulcerative colitis refractory intolerant therapy 5ASA , steroid , immunosuppressant antiTNFalpha . Endoscopic evidence active mucosal disease assess flexible sigmoidoscopy , DAI mucosal appearance sub score ≥ 2 . DAI rectal bleeding sub score ≥ 1 . Physician 's Global Assessment ( PGA ) DAI sub score ≥ 2 . Ability adhere study visit schedule protocol requirement . Ability provide voluntary write informed consent . Adequate cardiac , renal hepatic function determine site principal investigator demonstrate screen laboratory evaluation , questionnaire , physical examination result within normal limit . History colonic rectal surgery . Pregnant breastfeeding . Diagnosis diabetes , heart failure , unstable angina , hepatic cirrhosis , kidney failure , unstable medical condition . Known hypersensitivity Natura alpha drug excipients . Active chronic infection . Severe ulcerative colitis indicate Disease Activity Index score &gt; 10 . Patients ulcerative proctitis ( disease limit less 15 cm anal verge ) . Use vaccine immunostimulator within 4 week prior screen visit . . Use &gt; 2.4 gm mesalamine equivalent within 2 week prior screen visit . Use oral corticosteroid 3 day two week prior screen visit . Use corticosteroid 5ASA enema , foam , suppository time within two week prior screen visit . . Use TNFalpha antibody biologic therapy within 2 month prior screen visit . . Use immunosuppressive drug time within four week prior screen visit . . Use oral parenteral antibiotic time within two week prior screen visit . Diagnosis Crohn 's disease . Diagnosis indeterminate colitis ( inability distinguish ulcerative colitis Crohn 's disease ) . Diagnosis microscopic colitis ( collagenous lymphocytic colitis ) . Diagnosis ischemic , infectious ( e.g. , salmonella , shigella , etc . ) , amebic colitis , gonococcal proctitis . Diagnosis Clostridium difficile colitis . History positive serology hepatitis B C human immunodeficiency virus ( HIV ) infection . Active alcohol drug abuse . Known malignancy history malignancy would reduce life expectancy . Current smoker , smoker within 6 month prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Natura-alpha</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>cytokine</keyword>
	<keyword>Th1</keyword>
	<keyword>Th17</keyword>
</DOC>